Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares traded -0.97% lower at $2.05 on Wall Street last session.
In accordance with the data, 7 analysts cover Inovio Pharmaceuticals Inc. (NASDAQ:INO). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $3.00 and a low of $2.00, we find $2.00. Given the previous closing price of $2.07, this indicates a potential downside of -3.38 percent. INO stock price is now 5.90% away from the 50-day moving average and -14.71% away from the 200-day moving average. The market capitalization of the company currently stands at $561.86M.
It has been rated a hold by 6 analysts and a buy by 0. Brokers who have rated the stock have averaged $2.25 as their price target over the next twelve months.
On November 01, 2022, BofA Securities Downgraded its previous ‘Neutral’ rating to ‘Underperform’ on the stock keeping its target price maintained at $2, while ‘RBC Capital Mkts’ rates the stock as ‘Sector Perform’.
In other news, Weiner David B., Director sold 11,875 shares of the company’s stock on Aug 11. The stock was sold for $31,588 at an average price of $2.66. Upon completion of the transaction, the Director now directly owns 892,625 shares in the company, valued at $1.83 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 20, Director BENITO SIMON X sold 2,000 shares of the business’s stock. A total of $4,500 was realized by selling the stock at an average price of $2.25. This leaves the insider owning 75,305 shares of the company worth $0.15 million. Insiders disposed of 273,467 shares of company stock worth roughly $0.56 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in INO stock. A new stake in Inovio Pharmaceuticals Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $4,301,000. CUBIST SYSTEMATIC STRATEGIES, LLC invested $877,000 in shares of INO during the first quarter. In the first quarter, DIMENSIONAL FUND ADVISORS LP acquired a new stake in Inovio Pharmaceuticals Inc. valued at approximately $366,000. CAXTON ASSOCIATES LP acquired a new stake in INO for approximately $268,000. GRAHAM CAPITAL MANAGEMENT, L.P. purchased a new stake in INO valued at around $118,000 in the second quarter. In total, there are 258 active investors with 47.80% ownership of the company’s stock.
Inovio Pharmaceuticals Inc. (NASDAQ: INO) opened at $2.0600 on Wednesday. During the past 12 months, Inovio Pharmaceuticals Inc. has had a low of $1.38 and a high of $7.77. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 3.70, and a quick ratio of 3.70. The fifty day moving average price for INO is $1.9368 and a two-hundred day moving average price translates $2.3956 for the stock.
The latest earnings results from Inovio Pharmaceuticals Inc. (NASDAQ: INO) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.46, missing analysts’ expectations of -$0.31 by -0.15. This compares to -$0.29 EPS in the same period last year. The company reported revenue of $9.15 million for the quarter, compared to $0.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3034.93 percent. For the current quarter, analysts expect INO to generate $620k in revenue.
Inovio Pharmaceuticals Inc.(INO) Company Profile
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.